News | Radiopharmaceuticals and Tracers | January 11, 2023

Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium

Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium

January 11, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, announced it has achieved a major milestone in advancing its new technology for non-uranium based production of the critical medical radioisotope, molybdenum-99 (Mo-99). NorthStar’s proprietary electron accelerator technology has successfully produced Mo-99 at its recently completed Accelerator Production facility on its Beloit, Wis. campus. The “two beams on target” accelerator approach is highly efficient, with the potential to nearly double NorthStar’s commercial-scale Mo-99 capability with a single target set, and augments NorthStar’s ongoing domestic Mo-99 production in collaboration with the University of Missouri Research Reactor (MURR). Like all NorthStar processes, it uses non-uranium based technology that is independent of reliance on overseas nuclear reactors. NorthStar’s technology produces far less radioactive waste than uranium-based Mo-99 production processes, which makes the NorthStar process more environmentally friendly. The U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) provided financial and technical support for the project as part of its program to increase U.S. production of the vital medical radioisotope Mo-99 without the use of highly enriched uranium, which is a proliferation-sensitive material. Mo-99 is the parent radioisotope of technetium-99m (Tc-99m), the most widely used diagnostic imaging radioisotope, used to inform healthcare decisions for over 40,000 U.S. patients daily.

“This outstanding achievement of producing Mo-99 using electron accelerators marks another successful demonstration of how NorthStar continues to drive commercial-scale innovation solutions for industry to meet the needs of patients and advance clinical research,” said Frank Scholz, Ph.D., President and Chief Operating Officer of NorthStar Medical Radioisotopes. “Once our newly completed Accelerator Production facility is licensed and operational, NorthStar will have sufficient total production capability to meet nearly 40% of U.S. demand for Mo-99. This is particularly important given that the historically fragile overseas Mo-99 supply chain remains fraught with shortages, as recently as this past November, underscoring the continued need for domestic, reliable, non-uranium based Mo-99 supply for the United States. We are proud that our company can lead the way in supplying our RadioGenix System (technetium Tc 99m generator) customers with domestic Mo-99 despite these supply shortages, and we are excited by the prospect of bringing our Isotope Processing and Accelerator Production facilities online, upon completion of regulatory submissions, in mid-2023. We wish to express our deep appreciation for the great contributions in financial and technical support provided by DOE/NNSA in helping us to achieve this goal.”

“In 2018, NorthStar became the first U.S. company in nearly 30 years to produce Mo-99 domestically, using a non-uranium based process of irradiating and processing molybdenum-98 targets at MURR with neutron capture technology,” said James Harvey, Ph.D., Senior Vice President and Chief Science Officer of NorthStar Medical Radioisotopes. “NorthStar’s Accelerator Production facility in Beloit will be the first facility in the world to produce commercial-scale Mo-99 using this new technology. It is based on irradiation of molybdenum-100 targets with two electron beams rather than the currently used single beam approach used for the production of many other isotopes. Dual electron beam accelerator production is one of the most efficient methods of making Mo-99, and can also be used to produce therapeutic radioisotopes such as copper-67 (Cu-67) and non-carrier-added actinium-225 (n.c.a. Ac-225). It enables increased Mo-99 production capability, greater scheduling flexibility and results in a benign and easily managed waste stream.”

For more information: www.northstarnm.com

Related Radioisotope Content:    

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)  

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)    

Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal    

Update on Unplanned Outage of the HFR Reactor    

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply    

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals    

How Nuclear Fusion is Revolutionizing Medical Isotope Production    

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes    

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE    

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m 


Related Content

News | Lung Imaging

January 23, 2023 — A study published in the January issue of The Journal of Nuclear Medicine reports that approximately ...

Time January 23, 2023
arrow
News | Cardiac Imaging

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most ...

Time January 13, 2023
arrow
News | Molecular Imaging

January 5, 2023 — A new study has determined that approximately three percent of all bone scan patients have markers of ...

Time January 04, 2023
arrow
News | Nuclear Imaging

January 2, 2023 — The federal agency that oversees the administration of nuclear medicine has announced that it will ...

Time January 02, 2023
arrow
News | Proton Therapy

January 2, 2023 — IBA, a world leader in particle accelerator technology, today confirms that it has signed a contract ...

Time January 02, 2023
arrow
News | Proton Therapy

November 25, 2022 — Researchers at the University of Wisconsin–Madison, the first U.S. clinical evaluation site for GE ...

Time November 25, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
arrow
News | RSNA

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
News | Radiopharmaceuticals and Tracers

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time November 15, 2022
arrow
News | Radiopharmaceuticals and Tracers

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Time November 05, 2022
arrow
Subscribe Now